Ortoma AB (ORT-B) Fair Value & Analysis
Healthcare · SE · Market cap 400M SEK
Fair value as of: Jul 16, 2026
From 7 valuation models · updated 5 days ago
Fair value updated Jul 16, 2026, revised from kr 9.49 to kr 1.31 (−86.2%) since Jun 24, 2026. Share price +15.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 7.10 – kr 29.90 · fair‑value band kr 1.06 – kr 1.57 · the kr 8.57 price screens above the kr 1.31 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ortoma AB (ORT-B) currently trades at kr 8.57, while our model-based Fair Value estimate is kr 1.31, implying the stock looks roughly 84.7% overvalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 42.9M SEK. Revenue declined 60.2% year over year. It earns a return on equity of -26.5%. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 1.06 (bear case) to kr 1.57 (bull case); at kr 8.57, the current price sits above that range. The share trades about 74% below its 52-week high and 26% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -39% fair-value upside, at -85%, ORT-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Ortoma AB (publ) provides orthopedic surgical products in Sweden. It offers Ortoma Treatment Solution (OTS), an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up; OTS Plan, a software that processes and assists surgeons during pre-operative planning and post-operative follow-up; and OTS Guide, an intra-operative navigation tool guiding surgeons to place the implant in the pre-operatively planned position. The company was incorporated in 2001 and is based in Gothenburg, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ortoma AB reported revenue of kr 64.6M in FY2025 versus kr 0 in FY2021. Reported net income was −kr 19.2M in FY2025.
Is ORT-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $87.83 | $78.63 | -10% |
| Stryker Corporation SYK | $304.69 | $186.28 | -39% |
| Medtronic plc MDTC34 | R$203.91 | R$27.47 | -87% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EWL | €74.82 | €32.56 | -56% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| DexCom, Inc DXCM | $72.59 | $39.33 | -46% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥144.39 | ¥105.08 | -27% |
| Koninklijke Philips N.V PHG | $26.98 | $12.54 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ortoma AB (ORT-B) undervalued?
What is the fair value of ORT-B?
What is the quality score of ORT-B?
What is the revenue of Ortoma AB (ORT-B)?
What is the net profit margin of ORT-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Ortoma AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.